Association between activating KIR genes and risk for B-ALL in white patients of French-Canadian ancestry
| Gene . | Patients (n = 100), n (%) . | Control subjects (n = 245), n (%) . | OR (95% CI) . | P . |
|---|---|---|---|---|
| 2DS1 | 28 (28.3)** | 102 (41.6) | 0.55 (0.33-0.92) | .02 |
| 2DS2 | 20 (20.0) | 138 (56.3) | 0.19 (0.11-0.34) | 5.40 × 10−9 |
| 2DS3 | 14 (14.1)** | 83 (33.9) | 0.32 (0.17-0.60) | 3.70 × 10−4 |
| 2DS4* | 38 (39.2)** | 139 (56.7) | 0.49 (0.30-0.79) | .004 |
| 2DS5 | 19 (19.2)** | 104 (42.4) | 0.32 (0.18-0.56) | 7.50 × 10−5 |
| 3DS1 | 16 (16.0) | 101 (41.2) | 0.27 (0.15-0.49) | 1.57 × 10−5 |
| Gene . | Patients (n = 100), n (%) . | Control subjects (n = 245), n (%) . | OR (95% CI) . | P . |
|---|---|---|---|---|
| 2DS1 | 28 (28.3)** | 102 (41.6) | 0.55 (0.33-0.92) | .02 |
| 2DS2 | 20 (20.0) | 138 (56.3) | 0.19 (0.11-0.34) | 5.40 × 10−9 |
| 2DS3 | 14 (14.1)** | 83 (33.9) | 0.32 (0.17-0.60) | 3.70 × 10−4 |
| 2DS4* | 38 (39.2)** | 139 (56.7) | 0.49 (0.30-0.79) | .004 |
| 2DS5 | 19 (19.2)** | 104 (42.4) | 0.32 (0.18-0.56) | 7.50 × 10−5 |
| 3DS1 | 16 (16.0) | 101 (41.2) | 0.27 (0.15-0.49) | 1.57 × 10−5 |
The prefix KIR is not shown with the gene names.
OR indicates odds ratio; and CI, confidence interval.
KIR2DS4 was considered absent when the PCR amplified only the 22-bp deleted amplicon. It was considered present when the nonmutant amplicon was observed on the gel with or without the mutant band.
Percentages are based on 99 patients, as these genes could not be genotyped in 1 patient.